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Abstract
Mucins and their glycosylation have been suggested to play an important role in colorectal
carcinogenesis. We examined potentially functional genetic variants in the mucin genes or
genes involved in their glycosylation with respect to colorectal cancer (CRC) risk and clinical
outcome. We genotyped 23 single nucleotide polymorphisms (SNPs) covering 123 SNPs
through pairwise linkage disequilibrium (r2>0.80) in the MUC1, MUC2, MUC4, MUC5AC,
MUC6, and B3GNT6 genes in a hospital-based case-control study of 1532 CRC cases and
1108 healthy controls from the Czech Republic. We also analyzed these SNPs in relation to
overall survival and event-free survival in a subgroup of 672 patients. Among patients with-
out distant metastasis at the time of diagnosis, two MUC4 SNPs, rs3107764 and rs842225,
showed association with overall survival (HR 1.40, 95%CI 1.08–1.82, additive model, log-
rank p = 0.004 and HR 0.64, 95%CI 0.42–0.99, recessive model, log-rank p = 0.01, respec-
tively) and event-free survival (HR 1.31, 95%CI 1.03–1.68, log-rank p = 0.004 and HR 0.64,
95%CI 0.42–0.96, log-rank p = 0.006, respectively) after adjustment for age, sex and TNM
stage. Our data suggest that genetic variation especially in the transmembrane mucin gene
MUC4 may play a role in the survival of CRC and further studies are warranted.
Introduction
With a global incidence of 25.4/100,000 person-years, colorectal cancer (CRC) is the third
most common cancer diagnosed in men and second in women [1]. Individuals with a family







Citation: Lu S, Catalano C, Huhn S, Pardini B, Partu
L, Vymetalkova V, et al. (2019) Single nucleotide
polymorphisms within MUC4 are associated with
colorectal cancer survival. PLoS ONE 14(5):
e0216666. https://doi.org/10.1371/journal.
pone.0216666
Editor: Valli De Re, Istituto di Ricovero e Cura a
Carattere Scientifico Centro di Riferimento
Oncologico della Basilicata, ITALY
Received: January 7, 2019
Accepted: April 25, 2019
Published: May 15, 2019
Copyright: © 2019 Lu et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: This study was supported by the Ministry
of Health of the Czech Republic (AZV 15-27580A)
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history of CRC have an approximately 1.87 times higher risk of developing CRC than those
without a family history [2]. Lifetime risk for carriers of highly penetrant mutations in genes,
such as APC and mismatch repair genes, may reach 50%-80% [3]. In addition, 194 low-pene-
trance variants located in 144 loci have so far been associated with the risk of CRC by genome-
wide association studies (http://www.genome.gov/gwastudies/). Individuals carrying these var-
iants may also have a considerable risk of CRC [4]. Early identification of such individuals
could provide new options for clinical interventions and lead to cancer prevention and
improved treatment [3].
Genetic variation in inflammation-related genes is an attractive research target in the con-
text of CRC because inflammation is a known risk factor for CRC and a hallmark of human
cancer in general. The gut represents a unique environment for host-pathogen interactions,
with a commensal microflora in direct proximity of intestinal epithelial cells. Gut homeostasis
is maintained by a physical separation of the microbial community from the gut epithelium by
a mucous barrier. Secreted mucins form the physical barrier, while transmembrane mucins
contribute to the protective mucous gel through their O-glycosylated tandem repeats which
extend into the mucous gel [5]. The human mucin family consists of at least 22 members:
MUC1-MUC22 [5, 6].
It has been reported that reduced synthesis and secretion of mucins and altered O-glycosyl-
ation in mucus layer are related to the causation of human ulcerative colitis [7, 8]. Dysregula-
tion of mucin biosynthesis, especially of Muc2, and loss of core 1 and core 3-derived O-
glycans have been shown to induce colitis and CRC in murine models [9–11]. Intriguingly,
loss of core 3 synthase, which plays an important role in the synthesis of mucin-type O-glycans
in digestive organs, has also been shown to lead to development of colon cancer in a mouse
model [12].
Aberrant expression of mucins has been reported to be a common feature of CRC. MUC1
and MUC5AC have been shown to be up-regulated in CRC [13], and their overexpression has
been associated with disease progression [14–20]. For MUC2, down-regulation has been asso-
ciated both with CRC development and progression [14, 17, 18, 20, 21]. Aberrant expression
of MUC4 during CRC progression has also been reported, and overexpression of MUC4 has
been suggested to predict poor survival among patients with early stage (stage I and II) tumors
but not in patients with advanced-stage (stage III and IV) tumors [19, 22], Also MUC6 has
been suggested to be involved in CRC development [20, 23].
In addition to mucins, also the core 3 synthase, acetylgalactosaminyl-O-glycosyl-glycopro-
tein beta-1,3-N-acetylglucosaminyltransferase, encoded by the B3GNT6 gene in humans, has
been reported to be significantly down-regulated in colorectal cancer samples [24]. Due to this
expression change, it was suggested to be a marker for distinguishing benign adenomas and
premalignant lesions [24].
So far, few studies have investigated the association between genetic variants in the mucin
genes or genes involved to their glycosylation and CRC. Here, we genotyped a set of potentially
functional SNPs in the MUC1, MUC2, MUC4, MUC5AC, MUC6, and B3GNT6 genes in a
case-control study of 1532 CRC patients and 1108 healthy controls from the Czech Republic
and evaluated their association with CRC susceptibility, progression, and prognosis.
Materials and methods
Study population
The case group contained 1532 CRC patients recruited between the years 2004 and 2013 in an
on-going study by nine oncological departments in the Czech Republic and has been described
in detail previously [25–27]. Their mean age was 63 years (range 25–91), and 61.2% of them
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were males. The patients showed positive colonoscopic results for malignancy, histologically
confirmed as colon or rectal carcinomas. Patients who met the Amsterdam criteria I or II for
hereditary nonpolyposis colorectal cancer were not included in the study. General information
about gender and age at diagnosis was available for all patients. For 672 consecutively
recruited, incident cases diagnosed between 2003 and 2013, clinical data at the time of diagno-
sis, including location of the tumor (colon/rectum) and International Union against Cancer
(UICC) TNM stage classification [size or direct extent of the primary tumor (T), degree of
spread to regional lymph nodes (N), presence of metastasis (M)] were available (Table 1). Also
data on distant metastasis, relapse, death and last contact with the treating physician were
collected.
The control group consisted of 1108 healthy individuals recruited by a blood-donor center
in one hospital in Prague. These disease-free individuals represent the general population of
the Czech Republic, which has a genetically quite uniform population [28]. Their mean age
was 47 years (range 18–94) and 53.3% of them were males. All participants were of Czech Cau-
casian origin
All procedures performed involving human participants were in accordance with the ethi-
cal standards of the institutional and/or national research committee and with the 1964 Hel-
sinki declaration and its later amendments or comparable ethical standards. The study was
approved by the ethical committees of the participating institutes, the Institute of Experimental
Medicine, Academy of Sciences of the Czech Republic, the Institute of Clinical and Experi-
mental Medicine and Faculty Thomayer Hospital, and the General University Hospital, all in
Table 1. Univariable analysis of colorectal cancer survival and known prognostic factors.
Parameter N 1 N 1,2 died (%) HR (95%CI) P value
Gender
Female 259 99 (38.22) 1
Male 413 204 (49.39) 1.43 (1.13–1.82) 0.003
Localisation
Colon 429 188 (43.82) 1
Rectum 241 113 (46.89) 1.11 (0.88–1.40) 0.39
T
T1, T2 160 38 (23.75) 1
T3, T4 492 247 (50.20) 2.31 (1.64–3.25) <0.0001
N
N0 352 100 (28.41) 1
N1, N2 285 173 (60.70) 2.66 (2.08–3.41) <0.0001
M
M0 494 157 (31.78) 1
M1 178 146 (82.02) 3.90 (3.09–4.91) <0.0001
TNM Stage
Stage I 122 25 (20.94) 1
Stage II 195 49 (25.13) 1.07 (0.66–1.73) 0.8
Stage III 177 83 (46.89) 2.26 (1.44–3.53) 0.0004
Stage IV 178 146 (82.02) 5.70 (3.72–8.74) < .0001
1Number of cases may differ due to missing data
2Includes only individuals who died during the follow-up time
N, number of patients; HR, hazard ratio; CI, confidence interval. Bold numbers indicate a statistical significance at
5% level
https://doi.org/10.1371/journal.pone.0216666.t001
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Prague, Czech Republic. Written informed consent was obtained from all individual partici-
pants included in this study.
SNP selection and functional prediction of the associated variants
Five first and most studied mucin genes MUC1, 2, 4, 5AC and 6 and the gene encoding the
core 3 synthase, B3GNT6, which plays an important role in the synthesis of mucin-type O-gly-
cans in digestive organs, were selected as candidate genes based on their functional role in
CRC development and progression. A total of 23 SNPs were selected in these genes from the
International HapMap Project (http://hapmap.ncbi.nlm.nih.gov) and the NCBI database
(http://www.ncbi.nlm.nih.gov) (Table 2) based on the criteria described in[26]: location within
the coding region (non-synonymous SNPs), the 3’ and 5’ untranslated regions (UTRs) and the
promoter (up to approximately 1 kb from the transcription start site), pairwise linkage disequi-
librium (LD, r2�0.80) between the SNPs in Utah residents with Northern and Western Euro-
pean ancestry from the CEPH collection (CEU). We selected only SNPs with the minor allele
frequency (MAF)� 10% in Europeans, to minimize statistical uncertainties in the survival
analysis. The selected SNPs provided information on altogether 123 SNPs due to LD
(r2>0.80). For the SNPs, which associated with CRC risk or survival, SNPnexus (http://snp-
nexus.org/) was used to predict functional consequences of the selected SNPs. We also used
additional web-based tools [HaploReg v2 (http://www.broadinstitute.org), Regulome DB
(http://regulome.stanford.edu/) and SNPinfo Web Server (http://snpinfo.niehs.nih.gov/cgi-
bin/snpinfo/snpfunc.cgi)] to predict their effects on potential regulatory elements.
Genotyping
As described in detail in our previous study, whole genome amplified (WGA) DNA from
peripheral blood leukocytes was used [29]. All WGA samples were genotyped for two common
SNPs: less than 0.1% of the genotypes could not be determined or they did not agree with the
corresponding genomic DNA sample, confirming the accuracy of WGA. KASP (LGC Geno-
mics) or TaqMan (Applied Biosystems) allelic discrimination methods were used to genotype
the selected SNPs. DNA amplification was performed according to the LGC Genomics’ and
TaqMan´s PCR conditions. Case and control samples were amplified simultaneously in
384-well format using Hydrocycler 16 (LGC Genomics). Endpoint genotype detection was car-
ried out on the ViiA 7 Real-Time PCR System (Applied Biosystems). The sample set contained
142 duplicated samples as quality controls. The genotype correlation between the duplicate
samples was > 99%.
Statistical analysis
The observed genotype frequencies in the controls were tested for Hardy–Weinberg equilib-
rium (HWE) using the chi-square test. Odds ratios (ORs) and 95% confidence intervals (CIs)
for associations between genotypes and CRC risk were calculated by logistic regression (PROC
LOGISTIC, SAS Version 9.3; SAS Institute, Cary, NC), and adjusted for age and gender. Co-
dominant, dominant and recessive models were calculated to evaluate the statistical signifi-
cance. The major allele homozygous genotype was used as the reference. In the case of reces-
sive model, a combination of major allele homozygous and heterozygous genotypes was used
as the reference. To account for multiple testing, the SNP Spectral Deposition (SNPSpD)
method for multilocus analyses was applied. For a polymorphism with a variant allele fre-
quency between 10 and 50%, the study had greater than 90% power to detect an OR of 1.50 at
a significance level of 0.05 (PS—software for power and sample size calculation, http://biostat.
mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize). In this study, we analyzed overall
SNPs within MUC4 in CRC
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survival both in the 672 CRC patients diagnosed between 2003 and 2013 and in a subgroup of
494 patients with non-metastatic disease at the time of diagnosis, using the date of death or last
contact with the treating physician as the end point of follow-up. Median follow-up time for
the 672 patients was 58 months, while for patients who did not have distant metastasis at the
time of diagnosis it was 65 months. For event-free survival in patients with non-metastatic dis-
ease at the time of diagnosis, date of distant metastasis, relapse, death or last contact with the
treating physician was used as the end point of follow-up. Median follow-up time was 55
months. Survival curves for overall and event-free survival were derived by the Kaplan–Meier
method (PROC LIFETEST, SAS Version 9.3) and compared using log-rank test. The relative
risk of death was estimated as hazard ratio (HR) using Cox regression (PROC PHREG, SAS
Version 9.2). Multivariable survival analyses were adjusted for age, gender, T, N, M, TNM
stage and grade separately, and in a final model for age, sex, and TNM stage. Proportional haz-
ards assumption was tested and the assumption was fulfilled for all SNPs.
Results
Altogether, 123 SNPs with MAF� 10% in the CEU population were located within the regions
of interest (promoter, 5’- and 3’-UTR, non-synonymous SNPs) of the 6 genes MUC (1, 2, 4,
5AC, 6) and B3GNT6. From these, 23 SNPs were selected for genotyping based on LD
(r2�0.80) (Table 2). The genotype distribution of all genotyped polymorphisms was consistent
with HWE in the control group (P>0.05), except for rs72842418 (MUC6), which was excluded
from the analyses. The MAFs in the control population were similar to the ones reported by
the HapMap project for the CEU population.
Minor allele carriers of the MUC6 5’UTR SNP rs61869016 had a decreased risk of CRC
(OR 0.78, 95%CI 0.64–0.96, p = 0.02) (S1 Table). To correct for multiple testing, we used the
SNPSpD approach. The study-wise effective number of independent markers Meff was calcu-
lated to be 18, which gave the significance threshold of 0.0028. Thus, the association with the
SNP rs61869016 (MUC6) did not remain formally significant (P = 0.02).
In the univariable analysis, the following parameters were associated with overall survival
rate: gender, T, N, M and TNM stage (Table 1). Three SNPs, rs58116088 in B3GNT6 and
rs2071175 and rs2856111 in MUC2, showed nominal associations with overall survival among
the 672 patients with follow-up data after adjustment for age, sex and TNM stage (HR 0.78,
95%CI 0.62–0.99, dominant model, HR 4.47, 95%CI 1.09–18.30 for TT homozygotes, HR 2.55,
95%CI 1.25–5.21 for CC homozygotes, respectively, S2 Table). Interestingly, among patients
without distant metastasis at the time of diagnosis two MUC4 SNPs, rs3107764 and rs842225,
showed associations with overall survival (HR 1.40, 95%CI 1.08–1.82, additive model and HR
0.64, 95%CI 0.42–0.99, recessive model, respectively) and event-free survival (HR 1.31, 95%CI
1.03–1.68 and HR 0.64, 95%CI 0.42–0.96, respectively) after adjustment for age, sex and TNM
stage (Table 3). The Kaplan-Meier survival curves representing survival rates of the patients
according to their rs3107764 and rs842225 genotypes are presented in Fig 1. The overall and
event-free survival differences of the patients without distant metastasis at the time of diagno-
sis between the carriers of the different genotypes were statistically significant for rs3107764 in
the 3-genotype model with log-rank p-values of 0.004 (overall survival) and 0.004 (event-free
survival), respectively, and for rs842225 in recessive model with log-rank p-values of 0.01 and
0.006, respectively.
Discussion
Several mucin-type O-glycans have been considered as prognostic markers in CRC due to
their aberrant expression [15, 18, 20, 22, 24]. Recently, their interaction with Wnt/β-catenin
SNPs within MUC4 in CRC
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Table 2. Polymorphisms evaluated in this study.
dbSNP rs# Alleles Gene Chromosome Location MAF1 SNP captured with r2� 0.802
rs12743084 G/C MUC1 1q22 Exon 0.415
rs4072037 A/G MUC1 1q22 Exon 0.37 rs12411216 rs2974937 rs370545 rs914615
rs2066981 rs11355526 rs2075570 rs28445596
rs2990220 rs497829 rs2049805 rs2974931
rs2974930 rs2974929 rs2990245 rs2974935
rs11825977 A/G MUC2 11p15.5 Exon 0.226
rs2071175 C/T MUC2 11p15.5 Promotor 0.1
rs2856111 C/T MUC2 11p15.5 Exon 0.105
rs3749331 C/T MUC4 3q29 Exon 0.24 rs62284986 rs62282501 rs60632417
rs3107764 C/G MUC4 3q29 Exon 0.4
rs2246901 A/C MUC4 3q29 Exon 0.167
rs842225 A/G MUC4 3q29 5’ UTR 0.48
rs35783651 G/C MUC5ac 11p15.5 Exon 0.15 rs28513455 rs28699476 rs34974357 rs28653192
rs35705491 rs34462515 rs35779873 rs34831688
rs35288961 rs35525357 rs35968147 rs28728088
rs3087562 rs13010 rs11347 rs13380
rs28562881 rs28666868 rs28429038 rs28504415
rs28414902 rs150936581 rs35915689 rs141032511
rs35700114
rs17859812 G/A MUC5ac 11p15.5 5’ UTR 0.314 rs34664315 rs36021067 rs34207169 rs35396393
rs28691231 rs28542750 rs28737416 rs28434250
rs28524833 rs28645549 rs28639518 rs28468624
rs28569104 rs28520914 rs28633709 rs28663568
rs28464760 rs28972401 rs28550725 rs28653550
rs2075841 rs55898663 rs2075843 rs28457780 rs28439383 rs28520579 rs28519516 rs28545782
rs28558973 rs28368633 rs28731161 rs28399941 rs28414902 rs150936581 rs35915689 rs141032511
rs35700114
rs11604757 C/T MUC6 11p15.5 Exon 0.139
rs61869016 G/A MUC6 11p15.5 5’ UTR 0.39
rs6597947 A/C MUC6 11p15.5 5’ UTR 0.117 rs6597946
rs72842418 T/C MUC6 11p15.5 5’ UTR 0.131
rs7396383 A/T MUC6 11p15.5 Exon 0.2
rs7481521 C/T MUC6 11p15.5 Exon 0.434 rs12276666 rs12281858
rs12271271 G/A B3GNT6 11p15.5 5’ UTR 0.308 rs11237061
rs12422079 A/C B3GNT6 11p15.5 5’ UTR 0.293 rs34153015
rs58116088 G/A B3GNT6 11p15.5 3’ UTR 0.317 rs7115080 rs72949248 rs12575731 rs7103667
rs61902094 G/A B3GNT6 11p15.5 3’ UTR 0.142 rs77887719 rs61902097 rs61902099 rs11600516
rs58520141 rs61902104 rs11603853
rs6592699 A/G B3GNT6 11p15.5 5’ UTR 0.256 rs6592698 rs6592700 rs12292060 rs1894008
rs73493606 T/C B3GNT6 11p15.5 Exon 0.18 rs60414780 rs77669632 rs78494560 rs79335393
rs11600807 rs7110184 rs76695415 rs11605987
rs11237071 rs60341963 rs12274379 rs74567524
rs2186657 rs75007589 rs56839740 rs58336054
rs12284354 rs12270821 rs11237077 rs12291669 rs112674340 rs56937577
1Minor allele frequency (MAF) based on Utah residents with Northern and Western European ancestry from the CEPH collection in the HapMap project
2Pairwise linkage disequilibrium (r2) was calculated for the SNPs with MAF� 10% within the regions of interest based on Utah residents with Northern and Western
European ancestry from the CEPH collection in the HapMap project
https://doi.org/10.1371/journal.pone.0216666.t002
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signaling has been shown to play an important role in CRC progression [30]. In this genetic
association study, we investigated the associations between 23 SNPs capturing 123 potentially
functional SNPs in the mucin genes and B3GNT6 and CRC risk and clinical outcome. SNP
rs61869016 located in the MUC6 gene exhibited a nominal association with CRC risk. In the
multivariable survival analysis, two SNPs located in MUC4 were associated with overall and
event-free survival of non-metastatic CRC patients.
Table 3. Associations of rs2071175, rs58116088, rs3107764 and rs842225 with overall survival of all patients and overall and event-free survival among patients
without distant metastasis at the time of diagnosis (M = 0).
Gene SNP ID Genotype Overall Survival Analysis1
(adjusted for age, sex and
stage)
Overall Survival Analysis
(M = 0)2 adjusted for age, sex
and stage
Event-free Survival Analysis






















C/T 38 20 (52.63) 0.94 (0.59–
1.50)
0.81 26 11 (42.31) 1.47 (0.79–
2.76)
0.23 26 11 (42.31) 1.17 (0.63–
2.17)
0.63
T/T 4 2 (50.00) 4.47 (1.09–
18.30)
0.04 3 1 (33.33) 4.14 (0.56–
30.46)





C/T+ T/T 42 22 (52.38) 1.02 (0.66–
1.59)
0.93 29 12(41.38) 1.56 (0.85–
2.85)
0.15 29 12 (41.38) 1.22 (0.67–
2.22)
0.51
B3GNT6 rs58116088 G/G 239 115
(48.12)





0.07 242 72 (29.75) 0.77 (0.54–
1.09)
0.14 242 78(32.23) 0.78 (0.56–
1.09)
0.14
A/A 87 42 (48.28) 0.75 (0.53–
1.07)
0.11 61 19 (31.15) 0.75 (0.45–
1.27)





















0.84 215 65 (30.23) 1.13 (0.76–
1.69)
0.54 215 75 (34.88) 1.14 (0.79–
1.66)
0.48
C/C 86 40 (46.51) 1.06 (0.72–
1.55)
0.77 66 26 (39.39) 2.08 (1.26–
3.43)
0.004 66 28 (42.42) 1.79 (1.12–
2.88)
0.016


















0.7 216 69 (31.94) 0.92 (0.63–
1.34)
0.66 216 77 (35.65) 0.96 (0.68–
1.38)
0.84
A/A 144 63 (43.75) 0.96 (0.69–
1.34)
0.83 103 26 (25.24) 0.61 (0.37–
0.99)














A/A 144 63 (43.75) 0.93 (0.70–
1.23)
0.62 103 26 (25.24) 0.64 (0.42–
0.99)
0.04 103 28 (27.18) 0.64 (0.42–
0.96)
0.03
1Overall survival was calculated for all patients diagnosed between 2003 and 2013 (n = 672)
2Overall survival was calculated for patients diagnosed between 2003 and 2013, who did not have distant metastasis at the time of diagnosis (n = 494)
3Event-free survival was calculated for patients diagnosed between 2003 and 2013, who did not have distant metastasis at the time of diagnosis (n = 494)
4Number of cases may differ due to missing data.
5Includes only individuals who died during the follow-up time.
N, number of patients; OR, odds ratio; CI, confidence interval; Bold numbers indicate a statistical significance at 5% level; Ref, reference genotype(s)
https://doi.org/10.1371/journal.pone.0216666.t003
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MUC6 has recently been proposed as a prognostic marker for CRC patients [23]. Although
MUC6 expression was rarely observed in colorectal tumors, when it was present, the patients
had a very good prognosis [23]. In another study, MUC6 expression was associated with the
CpG island methylator phenotype (CIMP) of CRC and tumorigenesis via the serrated neopla-
sia pathway [31]. So far, most studies on polymorphisms in MUC6 have been dedicated to gas-
tric cancer, without any significant associations [32]. The only study on CRC reported no
association between a 3’UTR SNP and risk or clinical outcome [25]. In our study, this SNP
was captured by rs7481521 (r2 = 0.72) and similar to the previous study no association was
observed. However, we observed a nominally decreased risk among carriers of the minor allele
of rs61869016 in the 5’ UTR of MUC6. According to Regulome DB the SNP is located in a
region showing weak repressed Polycomb marks in different colorectal tissues, while in gastric
tissue, it shows enhancer marks. Thus, a potential mechanism how rs61869016 could affect
CRC risk is through tissue-specific regulation of gene expression via changes in histone state,
which may be relevant for the development of some specific types of CRC.
Previous reports have indicated that MUC4 expression is lost as CRC progresses, and this
loss of MUC4 may be regulated by β-catenin [33], however, in a subgroup of patients with
overexpression of MUC4 a worse prognosis has been reported [22, 34]. Through its epidermal
growth factor (EGF) domains, MUC4 may act as an intramembrane ligand for receptor tyro-
sine kinase ErbB2 and execute antiapoptotic function and by that promote tumor progression
[35, 36]. Published studies have reported that polymorphisms in MUC4 are associated with
susceptibility to lung cancer, endometriosis development and endometriosis-related infertility
[37, 38]; homozygous G allele carriers of the MUC4 SNP rs842225 were reported to have a
decreased risk of lung cancer in a Han Chinese population [35, 37, 38]. So far, no studies have
investigated the relationship between MUC4 SNPs and CRC. In our study, we found two SNPs
in MUC4, rs3107764 and rs842225, to be associated with overall and event-free survival
among patients without distant metastasis at the time of diagnosis. C allele carriers of
rs3107764 had an increased risk of dying while homozygous A allele carriers of rs842225 had a
decreased risk. Rs842225 is predicted to be likely to affect binding and expression of a target
gene (MUC20) by Regulome DB. Chromatin state data indicated also marks of strong tran-
scription at this locus in colon and rectal tissues. Rs3107764, on the other hand, is a missense
Fig 1. Kaplan-Meier analysis of survival among colorectal cancer patients without distant metastasis at diagnosis
(n = 494) according to genotypes of MUC4 rs3107764 and rs842225. (A) rs3107764: overall survival; (B) rs3107764:
event-free survival; (C) rs842225: overall survival; (D) rs842225: event-free survival.
https://doi.org/10.1371/journal.pone.0216666.g001
SNPs within MUC4 in CRC
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SNP (Ala41Pro), which is predicted to be possibly damaging by PolyPhen. It may also affect
expression of MUC20, although with a lower extent than rs842225. Previously, overexpression
of MUC20 has been associated with recurrence and poor survival of CRC patients [39].
Given the important role of the mucous barrier in maintaining the gut homeostasis, it is
surprising that only four studies have been published regarding potential associations between
genetic variants in the mucin genes and CRC [25, 40–42]. Similarly, studies on polymorphisms
in mucin genes or on alterations in mucin expression affecting risk of inflammatory bowel dis-
eases are sparse and inconclusive[43]. The four studies on SNPs and CRC risk reported either
no or only weak associations[25, 38–40], similar to our study. However, the study investigating
also associations with clinical outcome reported three associations between SNPs located in
the microRNA binding sites, recurrence and survival [25]. Interestingly, the genes involved
were MUC17, MUC20 and MUC21, all encoding transmembrane mucins, similar to MUC4,
which was identified in our study to affect both overall and event-free survival in metastasis-
free patients at the time of diagnosis. In addition to protecting gut epithelia against micro-
organisms and inflammation, transmembrane mucins also play an important role in transmit-
ting cell-cell and cell-microenvironment signals [5, 44]. In addition, they can induce cell trans-
formation and promote tumor progression [5, 44]. Thus, genetic variation in the regulatory
regions of the transmembrane mucin genes may modify the function of the corresponding
proteins and by that affect colorectal tumor progression and survival of the patients.
Our study has both strengths and limitations. The cases and controls represent a genetically
quite uniform Czech population [28], excluding the problem of population stratification. The
control group consisted of healthy blood donors, who may be more health conscious than the
general population. The control group was also younger and the proportion of men was lower
than in the case group. To avoid bias due to these differences, we adjusted our analyses for both
age and sex. From the 1532 CRC patients included in the study, 672 consecutively collected,
incident cases diagnosed between 2003 and 2013 were available for the survival analysis. This
ensured that only newly diagnosed CRC cases (within 1 year of diagnosis before enrollment for
this study) were included in the study, excluding a survival bias. For this subgroup, nearly com-
plete clinical data were available, allowing evaluation of the SNPs as independent prognostic
markers. However, although the number of individuals for the risk analysis was sufficient for
this kind of a study, the limitation to newly diagnosed CRC cases in the survival analyses
decreased the power to detect associations with genotypes. Because of that we concentrated on
SNPs with MAF� 10% in Europeans. Although we covered a total of 123 SNPs by the 23 geno-
typed SNPs in the basic regulatory and coding regions of the genes, it is possible that SNPs with
lower MAF or SNPs in still unknown regulatory regions of these genes, such as the enhancer
and the silencer regions, might also have an effect on CRC susceptibility or clinical outcome. As
our study covered only 6 of the known mucin and mucin-type O-glycosylation genes, further
studies are warranted in the other genes of this system maintaining the gut homeostasis.
In summary, our results on associations of SNPs in MUC4 with survival of CRC patients sup-
ports previous studies implicating importance of genetic variants in mucin genes encoding trans-
membrane mucins in the clinical outcome of CRC patients. Further studies with larger independent
populations are needed to verify our findings and to investigate the potential function of the studied
SNPs as well as SNPs in other relevant regulatory regions of the mucin-type O-glycans.
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